ProKidney Corp.

NASDAQ:PROK

Biotechnology

Healthcare
$1.04 +0.86%

+$0.02 today

Market cap
$349.70M
Beta
1.70
P/E (TTM)
-3.3
EPS (TTM)
-$0.53
52W Low $0.54High $7.13

Volume 1.80M

Average 0.96M

PROK EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

ProKidney Corp.NASDAQ: PROK

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$41.17M, compared with -$35.76M a year earlier. Trailing-twelve-month EBITDA was -$150.42M.

Context

  • EBITDA amounted to 16194.7% of revenue in FY2025, down 192347.4 pp from a year earlier.
  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 3 analysts of -$92.7M (+35.9%) for the fiscal year ending Dec 2026, a step up from the +8.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$41.17M-0.4% QoQ
Last fiscal yearDec 2025
-$144.62M+8.8% YoY
LTMMar 2026
-$150.42M+6.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.1%+20.9%+36.0 pp
1 year+8.8%+35.9%+27.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(144.62M) USD
Year-over-year change
+8.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How PROK compares with its peers on the latest reported figures

  • PROK's LTM Mar 2026 EBITDA of -$150.42M is the lowest of the 7 companies compared; the peer median is -$37.14M.
  • Its year-over-year change of +6.1% is the 2nd highest of 6, against a peer median of -164.0%.
  • EBITDA amounts to 16919.8% of revenue for PROK, versus a peer median of 16.4%.
PROK Competitors Peer median
EBITDA for PROK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MENSJyong Biotech Ltd. Ordinary SharesLTM Dec 2024-$1.94K ———
ARDXArdelyx, Inc.LTM Mar 2026-$25.52M +9.6%—6.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026-$35.03M -30.1%——
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.25M -164.0%——
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$106.58M -372.0%—16.4%
MAZEMaze Therapeutics, Inc.LTM Mar 2026-$119.51M -312.9%—597.6%
PROKProKidney Corp.LTM Mar 2026-$150.42M +6.1%—16919.8%
Peer median (excluding PROK) -$37.14M-164.0%—16.4%

Competitors are the stored peer set for PROK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00076K893K
Cost of Revenue00000
Gross Profit00076K893K
Gross Margin———100.0%100.0%
Research & Development46.26M82.07M106.71M127.67M114.12M
Selling, General & Admin8.86M70.94M44.82M56.08M51.78M
Operating Expenses55.11M153.01M151.52M183.75M165.9M
Depreciation & Amortization1.98M3.04M3.85M5.43M6.58M
EBITDA(53.12M)(143.99M)(125.59M)(158.49M)(144.62M)
EBITDA Margin———-208542.1%-16194.7%
Operating Income(55.11M)(153.01M)(151.52M)(183.68M)(165.01M)
Operating Margin———-241678.9%-18477.8%
Interest Income2K5.98M22.08M19.75M13.81M
Interest Expense0215K12K9K4K
Other Income / Expenses2K5.77M22.07M19.74M13.81M
Income Before Tax(55.11M)(147.24M)(129.45M)(163.93M)(151.2M)
Pre-Tax Margin———-215701.3%-16931.5%
Income Tax Expense38K896K6M(598K)414K
Net Income(55.15M)(108.03M)(35.47M)(61.19M)(68.99M)
Net Margin———-80507.9%-7725.2%
EPS (Basic)(1.73)(1.76)(0.57)(0.62)(0.52)
EPS (Diluted)(1.73)(1.76)(0.57)(0.62)(0.52)
Weighted Avg Shares31.89M61.54M61.71M97.92M133.94M
Weighted Avg Shares (Diluted)31.89M61.54M61.71M97.92M133.94M

ProKidney Corp.

NASDAQ:PROK

Intrinsic Alpha fair value

Locked

Current Price

$1.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.